{"id":30204,"date":"2024-04-09T14:26:00","date_gmt":"2024-04-09T04:26:00","guid":{"rendered":"https:\/\/template.reachmarkets.com.au\/investorportal\/?p=30204"},"modified":"2025-01-13T10:46:55","modified_gmt":"2025-01-13T00:46:55","slug":"prescient-therapeutics-investor-briefing","status":"publish","type":"post","link":"https:\/\/template.reachmarkets.com.au\/investorportal\/prescient-therapeutics-investor-briefing\/","title":{"rendered":"Prescient Therapeutics: Investor Briefing"},"content":{"rendered":"\n<section id=\"investor-briefing\" class=\"wp-block-gutentor-m3 section-gmfd8fb8f gutentor-module gutentor-container-cover has-image-bg has-custom-bg\"><div class=\"grid-container\">\n<section id=\"gm3127f84\" class=\"wp-block-gutentor-m4 section-gm3127f84 gutentor-module gutentor-advanced-columns\"><div class=\"grid-container\"><div class=\"grid-row\">\n<div id=\"col-gma100cf\" class=\"wp-block-gutentor-m4-col col-gma100cf gutentor-single-column  grid-lg-12 grid-md-12 grid-12\"><div id=\"section-gma100cf\" class=\"section-gma100cf gutentor-col-wrap\">\n<h2 class=\"wp-block-heading has-text-align-center has-white-color has-text-color\" style=\"font-size:33px\">Prescient Therapeutics: Investor Briefing with CEO and Managing Director, Steven Yatomi-Clarke<\/h2>\n\n\n\n<div style=\"height:30px\" aria-hidden=\"true\" class=\"wp-block-spacer\"><\/div>\n\n\n\n<p><\/p>\n<\/div><\/div>\n<\/div><\/div><\/section>\n\n\n\n<section id=\"gm743df17\" class=\"wp-block-gutentor-m4 section-gm743df17 gutentor-module gutentor-advanced-columns\"><div class=\"grid-container\"><div class=\"grid-row\">\n<div id=\"col-gmb6483b\" class=\"wp-block-gutentor-m4-col col-gmb6483b gutentor-single-column  grid-lg-7 grid-md-6 grid-12\"><div id=\"section-gmb6483b\" class=\"section-gmb6483b gutentor-col-wrap\">\n<figure class=\"wp-block-image size-full showvi\"><img loading=\"lazy\" decoding=\"async\" width=\"650\" height=\"360\" src=\"https:\/\/template.reachmarkets.com.au\/investorportal\/wp-content\/uploads\/2025\/01\/Page-3-Prescient-Therapeutics-Investor-Briefing-THUMBNAIL.png\" alt=\"\" class=\"wp-image-30205\" srcset=\"https:\/\/template.reachmarkets.com.au\/investorportal\/wp-content\/uploads\/2025\/01\/Page-3-Prescient-Therapeutics-Investor-Briefing-THUMBNAIL.png 650w, https:\/\/template.reachmarkets.com.au\/investorportal\/wp-content\/uploads\/2025\/01\/Page-3-Prescient-Therapeutics-Investor-Briefing-THUMBNAIL-300x166.png 300w\" sizes=\"auto, (max-width: 650px) 100vw, 650px\" \/><\/figure>\n\n\n\n<script src=\"https:\/\/ajax.googleapis.com\/ajax\/libs\/jquery\/3.5.1\/jquery.min.js\"><\/script>\n<script type=\"text\/javascript\"> \njQuery(document).ready(function ($) {\n    $('.showvi').click(function(e) {\n    e.preventDefault();\n  $('.showvi').html('<iframe loading=\"lazy\" src=\"https:\/\/player.vimeo.com\/video\/932372227?title=0&#038;byline=0&#038;portrait=0\" width=\"100%\" height=\"410\" frameborder=\"0\" allow=\"autoplay; fullscreen\" allowfullscreen><\/iframe>');\n});\n});\n\n <\/script>\n<script type=\"text\/javascript\">jQuery(document).ready(function($){\n    $(\".showvi\").append(\"<img class='play-icon play-video' src='https:\/\/reachmarkets.com.au\/wp-content\/uploads\/2019\/12\/play-icon-white.svg' \/>\");\n});<\/script>\n<\/div><\/div>\n\n\n\n<div id=\"col-gmb46ef2\" class=\"wp-block-gutentor-m4-col col-gmb46ef2 gutentor-single-column  grid-lg-5 grid-md-6 grid-12 homepage-custom\"><div id=\"section-gmb46ef2\" class=\"section-gmb46ef2 gutentor-col-wrap\">\n<p class=\"has-white-color has-text-color\">CEO and Managing Director, Steven Yatomi-Clarke, held an investor briefing with Reach Markets where he discussed the data from their Phase 1b trial, how they are well poised to progress toward commercialisation and how their other assets are progressing.<\/p>\n\n\n\n<p class=\"has-white-color has-text-color\">During the briefing, Steven discussed:<\/p>\n\n\n\n<ul class=\"wp-block-list white\">\n<li>Why the data from the PTX-100 Phase 1b trial is so promising, and why Prescient is on the cusp of a significant inflection point.<\/li>\n\n\n\n<li>The opportunities available for an effective therapy in T-cell lymphomas &#8211; a disease of unmet need.<\/li>\n\n\n\n<li>How the development pathway for PTX-100 could be considerably shorter and cheaper than conventional drug development paths.<\/li>\n\n\n\n<li>How Prescient&#8217;s $18m cash position allows them to go deep into a Phase 2 trial.<\/li>\n<\/ul>\n\n\n\n<p><\/p>\n\n\n\n<p class=\"has-white-color has-text-color\">Recorded on 9th April 2024 (AEDT)<\/p>\n\n\n\n<p><a href=\"https:\/\/template.reachmarkets.com.au\/investorportal\/investor-briefing\/\">Join the next Prescient Therapeutics webcast<\/a><\/p>\n\n\n\n<p><a href=\"https:\/\/template.reachmarkets.com.au\/investorportal\/register\/\">Register to stay up to date with Prescient Therapeutics<\/a><\/p>\n<\/div><\/div>\n<\/div><\/div><\/section>\n\n\n\n<section id=\"bio\" class=\"wp-block-gutentor-m3 alignwide section-gm92fd596 gutentor-module gutentor-container-cover custom-fullwidth\"><div class=\"grid-container\">\n<h4 class=\"wp-block-heading speak has-text-color\" style=\"color:#ffcc00\">Featured Speaker<\/h4>\n\n\n\n<h3 class=\"wp-block-heading has-text-align-center speaker-heading has-white-color has-text-color\"><\/h3>\n\n\n\n<section id=\"gm5c533fd\" class=\"wp-block-gutentor-m4 section-gm5c533fd gutentor-module gutentor-advanced-columns\"><div class=\"grid-container\"><div class=\"grid-row\">\n<div id=\"col-gmfcdb6b\" class=\"wp-block-gutentor-m4-col col-gmfcdb6b gutentor-single-column  grid-lg-3 grid-md-12 grid-12\"><div id=\"section-gmfcdb6b\" class=\"section-gmfcdb6b gutentor-col-wrap\"><\/div><\/div>\n\n\n\n<div id=\"col-gm0eb262\" class=\"wp-block-gutentor-m4-col col-gm0eb262 gutentor-single-column  grid-lg-6 grid-md-12 grid-12\"><div id=\"section-gm0eb262\" class=\"section-gm0eb262 gutentor-col-wrap\">\n<figure class=\"wp-block-image size-full speaker-img\"><img loading=\"lazy\" decoding=\"async\" width=\"300\" height=\"300\" src=\"https:\/\/template.reachmarkets.com.au\/investorportal\/wp-content\/uploads\/2022\/07\/SYC-cropped.jpg\" alt=\"\" class=\"wp-image-27331\" srcset=\"https:\/\/template.reachmarkets.com.au\/investorportal\/wp-content\/uploads\/2022\/07\/SYC-cropped.jpg 300w, https:\/\/template.reachmarkets.com.au\/investorportal\/wp-content\/uploads\/2022\/07\/SYC-cropped-150x150.jpg 150w\" sizes=\"auto, (max-width: 300px) 100vw, 300px\" \/><\/figure>\n\n\n\n<div style=\"height:20px\" aria-hidden=\"true\" class=\"wp-block-spacer\"><\/div>\n\n\n\n<h3 class=\"wp-block-heading has-text-align-center speaker-heading has-white-color has-text-color\">Steven Yatomi-Clarke<\/h3>\n\n\n\n<h4 class=\"wp-block-heading has-text-align-center speaker-title has-white-color has-text-color\">CEO and Managing Director<\/h4>\n\n\n\n<div style=\"height:20px\" aria-hidden=\"true\" class=\"wp-block-spacer\"><\/div>\n\n\n\n<p class=\"has-text-align-center speaker-bio has-white-color has-text-color\">Steven took over as CEO of Prescient Therapeutics in 2016 and has overseen its progression from start-up phase. Steven manages a team in Australia and the US and has been instrumental in strategy development; licensing; initiating and managing clinical trials; fundraising and business development.<\/p>\n\n\n\n<p class=\"has-text-align-center speaker-bio has-white-color has-text-color\">Previously, Steven had a distinguished career as an investment banker specialising in the life sciences sector, where he was consistently one of the country\u2019s most prolific bankers, involved in primary and secondary offerings, corporate advisory and M&amp;A assignments. In particular, Steven leveraged his combined backgrounds in science and finance to identify undervalued and unlikely opportunities and structure deals for the mutual benefit of companies and investors.<\/p>\n\n\n\n<p class=\"has-text-align-center speaker-bio has-white-color has-text-color\">Steven holds a Bachelor of Science with an Honours Degree in Biochemistry and Molecular Biology, and a Bachelor Commerce majoring in Economics, both from the University of Melbourne. He has been a collaborator on various immunotherapy research projects.<\/p>\n<\/div><\/div>\n\n\n\n<div id=\"col-gmd037a3\" class=\"wp-block-gutentor-m4-col col-gmd037a3 gutentor-single-column  grid-lg-3 grid-md-12 grid-12\"><div id=\"section-gmd037a3\" class=\"section-gmd037a3 gutentor-col-wrap\">\n<div style=\"height:20px\" aria-hidden=\"true\" class=\"wp-block-spacer\"><\/div>\n\n\n\n<h3 class=\"wp-block-heading has-text-align-center speaker-heading has-white-color has-text-color\"><\/h3>\n<\/div><\/div>\n<\/div><\/div><\/section>\n<\/div><\/section>\n<\/div><\/section>\n","protected":false},"excerpt":{"rendered":"","protected":false},"author":1,"featured_media":30205,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[6],"tags":[29],"class_list":["post-30204","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-video","tag-prescient-therapeutics"],"gutentor_comment":0,"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.2 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Prescient Therapeutics: Investor Briefing - PTX Therapeutics<\/title>\n<meta name=\"robots\" content=\"noindex, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Prescient Therapeutics: Investor Briefing - PTX Therapeutics\" \/>\n<meta property=\"og:url\" content=\"https:\/\/template.reachmarkets.com.au\/investorportal\/prescient-therapeutics-investor-briefing\/\" \/>\n<meta property=\"og:site_name\" content=\"PTX Therapeutics\" \/>\n<meta property=\"article:published_time\" content=\"2024-04-09T04:26:00+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2025-01-13T00:46:55+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/template.reachmarkets.com.au\/investorportal\/wp-content\/uploads\/2025\/01\/Page-3-Prescient-Therapeutics-Investor-Briefing-THUMBNAIL.png\" \/>\n\t<meta property=\"og:image:width\" content=\"650\" \/>\n\t<meta property=\"og:image:height\" content=\"360\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"author\" content=\"enouvoteam\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"enouvoteam\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\/\/template.reachmarkets.com.au\/investorportal\/prescient-therapeutics-investor-briefing\/#article\",\"isPartOf\":{\"@id\":\"https:\/\/template.reachmarkets.com.au\/investorportal\/prescient-therapeutics-investor-briefing\/\"},\"author\":{\"name\":\"enouvoteam\",\"@id\":\"https:\/\/template.reachmarkets.com.au\/investorportal\/#\/schema\/person\/a8a1e44025daf516a2ef27b38bef910c\"},\"headline\":\"Prescient Therapeutics: Investor Briefing\",\"datePublished\":\"2024-04-09T04:26:00+00:00\",\"dateModified\":\"2025-01-13T00:46:55+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\/\/template.reachmarkets.com.au\/investorportal\/prescient-therapeutics-investor-briefing\/\"},\"wordCount\":309,\"commentCount\":0,\"image\":{\"@id\":\"https:\/\/template.reachmarkets.com.au\/investorportal\/prescient-therapeutics-investor-briefing\/#primaryimage\"},\"thumbnailUrl\":\"https:\/\/template.reachmarkets.com.au\/investorportal\/wp-content\/uploads\/2025\/01\/Page-3-Prescient-Therapeutics-Investor-Briefing-THUMBNAIL.png\",\"keywords\":[\"Prescient Therapeutics\"],\"articleSection\":[\"Video\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\/\/template.reachmarkets.com.au\/investorportal\/prescient-therapeutics-investor-briefing\/#respond\"]}]},{\"@type\":\"WebPage\",\"@id\":\"https:\/\/template.reachmarkets.com.au\/investorportal\/prescient-therapeutics-investor-briefing\/\",\"url\":\"https:\/\/template.reachmarkets.com.au\/investorportal\/prescient-therapeutics-investor-briefing\/\",\"name\":\"Prescient Therapeutics: Investor Briefing - PTX Therapeutics\",\"isPartOf\":{\"@id\":\"https:\/\/template.reachmarkets.com.au\/investorportal\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\/\/template.reachmarkets.com.au\/investorportal\/prescient-therapeutics-investor-briefing\/#primaryimage\"},\"image\":{\"@id\":\"https:\/\/template.reachmarkets.com.au\/investorportal\/prescient-therapeutics-investor-briefing\/#primaryimage\"},\"thumbnailUrl\":\"https:\/\/template.reachmarkets.com.au\/investorportal\/wp-content\/uploads\/2025\/01\/Page-3-Prescient-Therapeutics-Investor-Briefing-THUMBNAIL.png\",\"datePublished\":\"2024-04-09T04:26:00+00:00\",\"dateModified\":\"2025-01-13T00:46:55+00:00\",\"author\":{\"@id\":\"https:\/\/template.reachmarkets.com.au\/investorportal\/#\/schema\/person\/a8a1e44025daf516a2ef27b38bef910c\"},\"breadcrumb\":{\"@id\":\"https:\/\/template.reachmarkets.com.au\/investorportal\/prescient-therapeutics-investor-briefing\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/template.reachmarkets.com.au\/investorportal\/prescient-therapeutics-investor-briefing\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/template.reachmarkets.com.au\/investorportal\/prescient-therapeutics-investor-briefing\/#primaryimage\",\"url\":\"https:\/\/template.reachmarkets.com.au\/investorportal\/wp-content\/uploads\/2025\/01\/Page-3-Prescient-Therapeutics-Investor-Briefing-THUMBNAIL.png\",\"contentUrl\":\"https:\/\/template.reachmarkets.com.au\/investorportal\/wp-content\/uploads\/2025\/01\/Page-3-Prescient-Therapeutics-Investor-Briefing-THUMBNAIL.png\",\"width\":650,\"height\":360},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/template.reachmarkets.com.au\/investorportal\/prescient-therapeutics-investor-briefing\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\/\/template.reachmarkets.com.au\/investorportal\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Prescient Therapeutics: Investor Briefing\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/template.reachmarkets.com.au\/investorportal\/#website\",\"url\":\"https:\/\/template.reachmarkets.com.au\/investorportal\/\",\"name\":\"PTX Therapeutics\",\"description\":\"\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/template.reachmarkets.com.au\/investorportal\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\/\/template.reachmarkets.com.au\/investorportal\/#\/schema\/person\/a8a1e44025daf516a2ef27b38bef910c\",\"name\":\"enouvoteam\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/secure.gravatar.com\/avatar\/525e472e47b8626f5328c05ecd1dfff7aa0511ab7833f7c361d41f240caaf9de?s=96&d=mm&r=g\",\"url\":\"https:\/\/secure.gravatar.com\/avatar\/525e472e47b8626f5328c05ecd1dfff7aa0511ab7833f7c361d41f240caaf9de?s=96&d=mm&r=g\",\"contentUrl\":\"https:\/\/secure.gravatar.com\/avatar\/525e472e47b8626f5328c05ecd1dfff7aa0511ab7833f7c361d41f240caaf9de?s=96&d=mm&r=g\",\"caption\":\"enouvoteam\"},\"sameAs\":[\"https:\/\/template.reachmarkets.com.au\/investorportal\"],\"url\":\"https:\/\/template.reachmarkets.com.au\/investorportal\/author\/enouvoteam\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Prescient Therapeutics: Investor Briefing - PTX Therapeutics","robots":{"index":"noindex","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"og_locale":"en_US","og_type":"article","og_title":"Prescient Therapeutics: Investor Briefing - PTX Therapeutics","og_url":"https:\/\/template.reachmarkets.com.au\/investorportal\/prescient-therapeutics-investor-briefing\/","og_site_name":"PTX Therapeutics","article_published_time":"2024-04-09T04:26:00+00:00","article_modified_time":"2025-01-13T00:46:55+00:00","og_image":[{"width":650,"height":360,"url":"https:\/\/template.reachmarkets.com.au\/investorportal\/wp-content\/uploads\/2025\/01\/Page-3-Prescient-Therapeutics-Investor-Briefing-THUMBNAIL.png","type":"image\/png"}],"author":"enouvoteam","twitter_card":"summary_large_image","twitter_misc":{"Written by":"enouvoteam","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/template.reachmarkets.com.au\/investorportal\/prescient-therapeutics-investor-briefing\/#article","isPartOf":{"@id":"https:\/\/template.reachmarkets.com.au\/investorportal\/prescient-therapeutics-investor-briefing\/"},"author":{"name":"enouvoteam","@id":"https:\/\/template.reachmarkets.com.au\/investorportal\/#\/schema\/person\/a8a1e44025daf516a2ef27b38bef910c"},"headline":"Prescient Therapeutics: Investor Briefing","datePublished":"2024-04-09T04:26:00+00:00","dateModified":"2025-01-13T00:46:55+00:00","mainEntityOfPage":{"@id":"https:\/\/template.reachmarkets.com.au\/investorportal\/prescient-therapeutics-investor-briefing\/"},"wordCount":309,"commentCount":0,"image":{"@id":"https:\/\/template.reachmarkets.com.au\/investorportal\/prescient-therapeutics-investor-briefing\/#primaryimage"},"thumbnailUrl":"https:\/\/template.reachmarkets.com.au\/investorportal\/wp-content\/uploads\/2025\/01\/Page-3-Prescient-Therapeutics-Investor-Briefing-THUMBNAIL.png","keywords":["Prescient Therapeutics"],"articleSection":["Video"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/template.reachmarkets.com.au\/investorportal\/prescient-therapeutics-investor-briefing\/#respond"]}]},{"@type":"WebPage","@id":"https:\/\/template.reachmarkets.com.au\/investorportal\/prescient-therapeutics-investor-briefing\/","url":"https:\/\/template.reachmarkets.com.au\/investorportal\/prescient-therapeutics-investor-briefing\/","name":"Prescient Therapeutics: Investor Briefing - PTX Therapeutics","isPartOf":{"@id":"https:\/\/template.reachmarkets.com.au\/investorportal\/#website"},"primaryImageOfPage":{"@id":"https:\/\/template.reachmarkets.com.au\/investorportal\/prescient-therapeutics-investor-briefing\/#primaryimage"},"image":{"@id":"https:\/\/template.reachmarkets.com.au\/investorportal\/prescient-therapeutics-investor-briefing\/#primaryimage"},"thumbnailUrl":"https:\/\/template.reachmarkets.com.au\/investorportal\/wp-content\/uploads\/2025\/01\/Page-3-Prescient-Therapeutics-Investor-Briefing-THUMBNAIL.png","datePublished":"2024-04-09T04:26:00+00:00","dateModified":"2025-01-13T00:46:55+00:00","author":{"@id":"https:\/\/template.reachmarkets.com.au\/investorportal\/#\/schema\/person\/a8a1e44025daf516a2ef27b38bef910c"},"breadcrumb":{"@id":"https:\/\/template.reachmarkets.com.au\/investorportal\/prescient-therapeutics-investor-briefing\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/template.reachmarkets.com.au\/investorportal\/prescient-therapeutics-investor-briefing\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/template.reachmarkets.com.au\/investorportal\/prescient-therapeutics-investor-briefing\/#primaryimage","url":"https:\/\/template.reachmarkets.com.au\/investorportal\/wp-content\/uploads\/2025\/01\/Page-3-Prescient-Therapeutics-Investor-Briefing-THUMBNAIL.png","contentUrl":"https:\/\/template.reachmarkets.com.au\/investorportal\/wp-content\/uploads\/2025\/01\/Page-3-Prescient-Therapeutics-Investor-Briefing-THUMBNAIL.png","width":650,"height":360},{"@type":"BreadcrumbList","@id":"https:\/\/template.reachmarkets.com.au\/investorportal\/prescient-therapeutics-investor-briefing\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/template.reachmarkets.com.au\/investorportal\/"},{"@type":"ListItem","position":2,"name":"Prescient Therapeutics: Investor Briefing"}]},{"@type":"WebSite","@id":"https:\/\/template.reachmarkets.com.au\/investorportal\/#website","url":"https:\/\/template.reachmarkets.com.au\/investorportal\/","name":"PTX Therapeutics","description":"","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/template.reachmarkets.com.au\/investorportal\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/template.reachmarkets.com.au\/investorportal\/#\/schema\/person\/a8a1e44025daf516a2ef27b38bef910c","name":"enouvoteam","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/525e472e47b8626f5328c05ecd1dfff7aa0511ab7833f7c361d41f240caaf9de?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/525e472e47b8626f5328c05ecd1dfff7aa0511ab7833f7c361d41f240caaf9de?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/525e472e47b8626f5328c05ecd1dfff7aa0511ab7833f7c361d41f240caaf9de?s=96&d=mm&r=g","caption":"enouvoteam"},"sameAs":["https:\/\/template.reachmarkets.com.au\/investorportal"],"url":"https:\/\/template.reachmarkets.com.au\/investorportal\/author\/enouvoteam\/"}]}},"_links":{"self":[{"href":"https:\/\/template.reachmarkets.com.au\/investorportal\/wp-json\/wp\/v2\/posts\/30204","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/template.reachmarkets.com.au\/investorportal\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/template.reachmarkets.com.au\/investorportal\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/template.reachmarkets.com.au\/investorportal\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/template.reachmarkets.com.au\/investorportal\/wp-json\/wp\/v2\/comments?post=30204"}],"version-history":[{"count":3,"href":"https:\/\/template.reachmarkets.com.au\/investorportal\/wp-json\/wp\/v2\/posts\/30204\/revisions"}],"predecessor-version":[{"id":30212,"href":"https:\/\/template.reachmarkets.com.au\/investorportal\/wp-json\/wp\/v2\/posts\/30204\/revisions\/30212"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/template.reachmarkets.com.au\/investorportal\/wp-json\/wp\/v2\/media\/30205"}],"wp:attachment":[{"href":"https:\/\/template.reachmarkets.com.au\/investorportal\/wp-json\/wp\/v2\/media?parent=30204"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/template.reachmarkets.com.au\/investorportal\/wp-json\/wp\/v2\/categories?post=30204"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/template.reachmarkets.com.au\/investorportal\/wp-json\/wp\/v2\/tags?post=30204"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}